Wojciech Legic

OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide

Purpose of the Study: Only 20%-30% of patients with relapsed/ refractory multiple myeloma (RRMM) respond to the next line of treatment, and ultimately most will relapse. Melflufen is a li...

Pieter Sonneveld ;

Fredrik Schjesvold ;

Pawel Robak ;

Viktor Rossjey ;

Sosana Delimpasi ;

Ludk Pour ;

Wojciech Legic ;

Catriona Byrne ;

Galina Salogub ;

Jiri Minarik ;

Johan Harmenberg ;

Paul G. Richardson ;

Eva Nordstrom ;

10/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Wojciech Legic

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products